Delineating an epigenetic continuum in head and neck cancer

Cancer Letters

Volumn 342, Issue 2, 2014, Pages 178-184

  Worsham, Maria J ^a   Stephen, Josena K ^a   Chen, Kang Mei ^a   Havard, Shaleta ^a   Shah, Veena ^a   Gardner, Glendon ^a   Schweitzer, Vanessa G ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Benign papillomas; DNA hypermethylation; Progression; Squamous cell carcinoma

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROTEIN P53;

CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CARCINOGENESIS; CHROMOSOME 9P; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; DNA METHYLATION; EPIGENETICS; GENE MUTATION; GENE SILENCING; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HISTOPATHOLOGY; HUMAN; LARYNX PAPILLOMATOSIS; MALIGNANT TRANSFORMATION; PAPILLOMA; PHENOTYPE; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; TUMOR SUPPRESSOR GENE;

EID: 84888200857     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.02.018     Document Type: Review

References (96)

1. Cancer Facts and Figures 2011. American Cancer Society, 2011.
2. Patel S.G., Shah J.P. TNM staging of cancers of the head and neck: striving for uniformity among diversity. CA Cancer J. Clin. 2005, 55:242-258. (quiz 261-242, 264).
3. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
4. Van Dyke D.L., Worsham M.J., Benninger M.S., Krause C.J., Baker S.R., Wolf G.T., Drumheller T., Tilley B.C., Carey T.E. Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosom. Cancer 1994, 9:192-206.
5. Carey T.E., Van Dyke D.L., Worsham M.J. Nonrandom chromosome aberrations and clonal populations in head and neck cancer. Anticancer Res. 1993, 13:2561-2567.
6. Carey T.E., Worsham M.J., Van Dyke D.L. Chromosomal biomarkers in the clonal evolution of head and neck squamous neoplasia. J. Cell. Biochem. Suppl. 1993, 17F:213-222.
7. Tabor M.P., Brakenhoff R.H., van Houten V.M., Kummer J.A., Snel M.H., Snijders P.J., Snow G.B., Leemans C.R., Braakhuis B.J. Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin. Cancer Res. 2001, 7:1523-1532.
8. Worsham M.J., Benninger M.J., Zarbo R.J., Carey T.E., Van Dyke D.L. Deletion 9p22-pter and loss of Y as primary chromosome abnormalities in a squamous cell carcinoma of the vocal cord. Genes Chromosom. Cancer 1993, 6:58-60.
9. Worsham M.J., Carey T.E., Benninger M.S., Gasser K.M., Kelker W., Zarbo R.J., Van Dyke D.L. Clonal cytogenetic evolution in a squamous cell carcinoma of the skin from a xeroderma pigmentosum patient. Genes Chromosom. Cancer 1993, 7:158-164.
10. Worsham M.J., Wolman S.R., Carey T.E., Zarbo R.J., Benninger M.S., Van Dyke D.L. Common clonal origin of synchronous primary head and neck squamous cell carcinomas: analysis by tumor karyotypes and fluorescence in situ hybridization. Hum. Pathol. 1995, 26:251-261.
11. Carey T.E., Frank C.J., Raval J.R., Jones J.W., McClatchey K.D., Beals T.F., Worsham M.J., Van Dyke D.L. Identifying genetic changes associated with tumor progression in squamous cell carcinoma. Acta Otolaryngol. Suppl. 1997, 529:229-232.
12. Partridge M., Emilion G., Pateromichelakis S., A'Hern R., Phillips E., Langdon J. Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral precancer, cumulative loss and its relationship with progression to cancer. Oral Oncol. 1998, 34:77-83.
13. Nemunaitis J., Nemunaitis J. Head and neck cancer: response to p53-based therapeutics. Head Neck 2011, 33:131-134.
14. Zhang H.S., Postigo A.A., Dean D.C. Active transcriptional repression by the Rb-E2F complex mediates G1 arrest triggered by p16INK4a, TGFbeta, and contact inhibition. Cell 1999, 97:53-61.
15. Worsham M.J., Chen K.M., Tiwari N., Pals G., Schouten J.P., Sethi S., Benninger M.S. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 2006, 132:409-415.
16. Yarbrough W.G. The ARF-p16 gene locus in carcinogenesis and therapy of head and neck squamous cell carcinoma. Laryngoscope 2002, 112:2114-2128.
17. Bova R.J., Quinn D.I., Nankervis J.S., Cole I.E., Sheridan B.F., Jensen M.J., Morgan G.J., Hughes C.J., Sutherland R.L. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin. Cancer Res. 1999, 5:2810-2819.
18. Costello J.F., Plass C. Methylation matters. J. Med. Genet. 2001, 38:285-303.
19. Li E., Bestor T.H., Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992, 69:915-926.
20. Li E., Beard C., Jaenisch R. Role for DNA methylation in genomic imprinting. Nature 1993, 366:362-365.
21. Pfeifer G.P., Tanguay R.L., Steigerwald S.D., Riggs A.D. In vivo footprint and methylation analysis by PCR-aided genomic sequencing: comparison of active and inactive X chromosomal DNA at the CpG island and promoter of human PGK-1. Genes Dev. 1990, 4:1277-1287.
22. Costello J.F., Fruhwald M.C., Smiraglia D.J., Rush L.J., Robertson G.P., Gao X., Wright F.A., Feramisco J.D., Peltomaki P., Lang J.C., Schuller D.E., Yu L., Bloomfield C.D., Caligiuri M.A., Yates A., Nishikawa R., Su Huang H., Petrelli N.J., Zhang X., O'Dorisio M.S., Held W.A., Cavenee W.K., Plass C. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat. Genet. 2000, 24:132-138.
23. Issa J.P., Vertino P.M., Wu J., Sazawal S., Celano P., Nelkin B.D., Hamilton S.R., Baylin S.B. Increased cytosine DNA-methyltransferase activity during colon cancer progression. J. Natl. Cancer Inst. 1993, 85:1235-1240.
24. Lin S.Y., Yeh K.T., Chen W.T., Chen H.C., Chen S.T., Chang J.G. Promoter CpG methylation of caveolin-1 in sporadic colorectal cancer. Anticancer Res. 2004, 24:1645-1650.
25. Smiraglia D.J., Smith L.T., Lang J.C., Rush L.J., Dai Z., Schuller D.E., Plass C. Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC). J. Med. Genet. 2003, 40:25-33.
26. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., Issa J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res. 1998, 72:141-196.
27. Jones P.A., Laird P.W. Cancer epigenetics comes of age. Nat. Genet. 1999, 21:163-167.
28. Chan M.F., Liang G., Jones P.A. Relationship between transcription and DNA methylation. Curr. Top. Microbiol. Immunol. 2000, 249:75-86.
29. Cairns P. Detection of promoter hypermethylation of tumor suppressor genes in urine from kidney cancer patients. Ann. NY Acad. Sci. 2004, 1022:40-43.
30. Kim H., Kwon Y.M., Kim J.S., Lee H., Park J.H., Shim Y.M., Han J., Park J., Kim D.H. Tumor-specific methylation in bronchial lavage for the early detection of non-small-cell lung cancer. J. Clin. Oncol. 2004, 22:2363-2370.
31. Roman-Gomez J., Jimenez-Velasco A., Castillejo J.A., Agirre X., Barrios M., Navarro G., Molina F.J., Calasanz M.J., Prosper F., Heiniger A., Torres A. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 2004, 104:2492-2498.
32. Olden K., Isaac L., Roberts L. Neighborhood-specific epigenome analysis: the pathway forward to understanding gene-environment interactions. NC Med. J. 2011, 72:125-127.
33. Garber K. Breaking the silence: the rise of epigenetic therapy. J. Natl. Cancer Inst. 2002, 94:874-875.
34. Kopelovich L., Crowell J.A., Fay J.R. The epigenome as a target for cancer chemoprevention. J. Natl. Cancer Inst. 2003, 95:1747-1757.
35. Lu D., Hoory T., Monie A., Wu A., Wang M.C., Hung C.F. Treatment with demethylating agent, 5-aza-2'-deoxycytidine enhances therapeutic HPV DNA vaccine potency. Vaccine 2009, 27:4363-4369.
36. Miracca E.C., Kowalski L.P., Nagai M.A. High prevalence of p16 genetic alterations in head and neck tumours. Brit. J. Cancer 1999, 81:677-683.
37. Esteller M., Corn P.G., Baylin S.B., Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res. 2001, 61:3225-3229.
38. Rosas S.L., Koch W., da Costa Carvalho M.G., Wu L., Califano J., Westra W., Jen J., Sidransky D. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 2001, 61:939-942.
39. Hasegawa M., Nelson H.H., Peters E., Ringstrom E., Posner M., Kelsey K.T. Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene 2002, 21:4231-4236.
40. Viswanathan M., Tsuchida N., Shanmugam G. Promoter hypermethylation profile of tumor-associated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma. Int. J. Cancer 2003, 105:41-46.
41. El-Naggar A.K., Lai S., Clayman G., Lee J.K., Luna M.A., Goepfert H., Batsakis J.G. Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma. Am. J. Pathol. 1997, 151:1767-1774.
42. Sanchez-Cespedes M., Esteller M., Wu L., Nawroz-Danish H., Yoo G.H., Koch W.M., Jen J., Herman J.G., Sidransky D. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 2000, 60:892-895.
43. Chen K., Sawhney R., Khan M., Benninger M.S., Hou Z., Sethi S., Stephen J.K., Worsham M.J. Methylation of multiple genes as diagnostic and therapeutic markers in primary head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 2007, 133:1131-1138.
44. Zou C.P., Youssef E.M., Zou C.C., Carey T.E., Lotan R. Differential effects of chromosome 3p deletion on the expression of the putative tumor suppressor RAR beta and on retinoid resistance in human squamous carcinoma cells. Oncogene 2001, 20:6820-6827.
45. Xu X.C., Ro J.Y., Lee J.S., Shin D.M., Hong W.K., Lotan R. Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res. 1994, 54:3580-3587.
46. Pegg A.E. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res. 1990, 50:6119-6129.
47. Hirohashi S. Inactivation of the E-cadherin-mediated cell adhesion system in human cancers. Am. J. Pathol. 1998, 153:333-339.
48. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 1996, 93:9821-9826.
49. Huang T.H., Perry M.R., Laux D.E. Methylation profiling of CpG islands in human breast cancer cells. Hum. Mol. Genet. 1999, 8:459-470.
50. Worsham M.J., Chen K.M., Meduri V., Nygren A.O., Errami A., Schouten J.P., Benninger M.S. Epigenetic events of disease progression in head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 2006, 132:668-677.
51. Smeets S.J., Braakhuis B.J., Abbas S., Snijders P.J., Ylstra B., van de Wiel M.A., Meijer G.A., Leemans C.R., Brakenhoff R.H. Genome-wide DNA copy number alterations in head and neck squamous cell carcinomas with or without oncogene-expressing human papillomavirus. Oncogene 2006, 25:2558-2564.
52. Worsham M.J., Pals G., Schouten J.P., Van Spaendonk R.M., Concus A., Carey T.E., Benninger M.S. Delineating genetic pathways of disease progression in head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 2003, 129:702-708.
53. Shaw R.J., Liloglou T., Rogers S.N., Brown J.S., Vaughan E.D., Lowe D., Field J.K., Risk J.M. Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Brit. J. Cancer 2006, 94:561-568.
54. Sanchez-Cespedes M., Okami K., Cairns P., Sidransky D. Molecular analysis of the candidate tumor suppressor gene ING1 in human head and neck tumors with 13q deletions. Genes Chromosom. Cancer 2000, 27:319-322.
55. Shah S.I., Yip L., Greenberg B., Califano J.A., Chow J., Eisenberger C.F., Lee D.J., Sewell D.A., Reed A.L., Lango M., Jen J., Koch W.M., Sidransky D. Two distinct regions of loss on chromosome arm 4q in primary head and neck squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 2000, 126:1073-1076.
56. Sidransky D., Circulating D.N.A. What we know and what we need to learn. Ann. NY Acad. Sci. 2000, 906:1-4.
57. Maruya S., Issa J.P., Weber R.S., Rosenthal D.I., Haviland J.C., Lotan R., El-Naggar A.K. Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications. Clin. Cancer Res. 2004, 10:3825-3830.
58. Nygren A.O., Ameziane N., Duarte H.M., Vijzelaar R.N., Waisfisz Q., Hess C.J., Schouten J.P., Errami A. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucl. Acids Res. 2005, 33:e128.
59. Capper J.W., Bailey C.M., Michaels L. Squamous papillomas of the larynx in adults. A review of 63 cases. Clin. Otolaryngol. Allied Sci. 1983, 8:109-119.
60. Bauman N.M., Smith R.J. Recurrent respiratory papillomatosis. Pediatr. Clin. North Am. 1996, 43:1385-1401.
61. Batsakis J.G., Suarez P. Schneiderian papillomas and carcinomas: a review. Adv. Anat. Pathol. 2001, 8:53-64.
62. Doyle D.J., Henderson L.A., LeJeune F.E., Miller R.H. Changes in human papillomavirus typing of recurrent respiratory papillomatosis progressing to malignant neoplasm. Arch. Otolaryngol. Head Neck Surg. 1994, 120:1273-1276.
63. Buchwald C., Franzmann M.B., Jacobsen G.K., Lindeberg H. Human papillomavirus (HPV) in sinonasal papillomas: a study of 78 cases using in situ hybridization and polymerase chain reaction. Laryngoscope 1995, 105:66-71.
64. Brandwein M., Steinberg B., Thung S., Biller H., Dilorenzo T., Galli R. Human papillomavirus 6/11 and 16/18 in Schneiderian inverted papillomas. In situ hybridization with human papillomavirus RNA probes. Cancer 1989, 63:1708-1713.
65. Mounts P., Shah K.V., Kashima H. Viral etiology of juvenile- and adult-onset squamous papilloma of the larynx. Proc. Natl. Acad. Sci. USA 1982, 79:5425-5429.
66. Gabbott M., Cossart Y.E., Kan A., Konopka M., Chan R., Rose B.R. Human papillomavirus and host variables as predictors of clinical course in patients with juvenile-onset recurrent respiratory papillomatosis. J. Clin. Microbiol. 1997, 35:3098-3103.
67. Gissmann L., Wolnik L., Ikenberg H., Koldovsky U., Schnurch H.G.,Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc. Natl. Acad. Sci. USA 1983, 80:560-563.
68. Syrjanen K.J. HPV infections in benign and malignant sinonasal lesions. J. Clin. Pathol. 2003, 56:174-181.
69. Syrjanen S., Happonen R.P., Virolainen E., Siivonen L., Syrjanen K. Detection of human papillomavirus (HPV) structural antigens and DNA types in inverted papillomas and squamous cell carcinomas of the nasal cavities and paranasal sinuses. Acta Otolaryngol. 1987, 104:334-341.
70. Hartley C., Hamilton J., Birzgalis A.R., Farrington W.T. Recurrent respiratory papillomatosis - the Manchester experience, 1974-1992. J. Laryngol. Otol. 1994, 108:226-229.
71. Lie E.S., Karlsen F., Holm R. Presence of human papillomavirus in squamous cell laryngeal carcinomas. A study of thirty-nine cases using polymerase chain reaction and in situ hybridization. Acta Otolaryngol. 1996, 116:900-905.
72. Katori H., Nozawa A., Tsukuda M. Markers of malignant transformation of sinonasal inverted papilloma. Eur. J. Surg. Oncol. 2005, 31:905-911.
73. Lele S.M., Pou A.M., Ventura K., Gatalica Z., Payne D. Molecular events in the progression of recurrent respiratory papillomatosis to carcinoma. Arch. Pathol. Lab. Med. 2002, 126:1184-1188.
74. Hyams V.J. Papillomas of the nasal cavity and paranasal sinuses. A clinicopathological study of 315 cases. Ann. Otol. Rhinol. Laryngol. 1971, 80:192-206.
75. Wormald P.J., Ooi E., van Hasselt C.A., Nair S. Endoscopic removal of sinonasal inverted papilloma including endoscopic medial maxillectomy. Laryngoscope 2003, 113:867-873.
76. Lawson W., Kaufman M.R., Biller H.F. Treatment outcomes in the management of inverted papilloma: an analysis of 160 cases. Laryngoscope 2003, 113:1548-1556.
77. Califano J., Koch W., Sidransky D., Westra W.H. Inverted sinonasal papilloma: a molecular genetic appraisal of its putative status as a Precursor to squamous cell carcinoma. Am. J. Pathol. 2000, 156:333-337.
78. Stephen J.K., Vaught L.E., Chen K.M., Sethi S., Shah V., Benninger M.S., Gardner G.M., Schweitzer V.G., Khan M., Worsham M.J. Epigenetic events underlie the pathogenesis of sinonasal papillomas. Mod. Pathol. 2007, 20:1019-1027.
79. Dedo H.H., Yu K.C. CO(2) laser treatment in 244 patients with respiratory papillomas. Laryngoscope 2001, 111:1639-1644.
80. Go C., Schwartz M.R., Donovan D.T. Molecular transformation of recurrent respiratory papillomatosis: viral typing and p53 overexpression. Ann. Otol. Rhinol. Laryngol. 2003, 112:298-302.
81. Kossak-Glowczewska M. Spontaneous neoplastic transformation of laryngeal papilloma in adults. Otolaryngol. Pol. 1991, 45:186-194.
82. Duggan M.A., Lim M., Gill M.J., Inoue M. HPV DNA typing of adult-onset respiratory papillomatosis. Laryngoscope 1990, 100:639-642.
83. Stephen J.K., Vaught L.E., Chen K.M., Shah V., Schweitzer V.G., Gardner G., Benninger M.S., Worsham M.J. An epigenetically derived monoclonal origin for recurrent respiratory papillomatosis. Arch. Otolaryngol. Head Neck Surg. 2007, 133:684-692.
84. Stephen J.K., Vaught L.E., Chen K.M., Shah V., Schweitzer V.G., Gardner G., Benninger M.S., Worsham M.J. Consistent aberrant DNA methylation patterns in laryngeal papillomas. Int. J. Head Neck Surg. 2010, 1:69-77.
85. Rabah R., Sakr W., Thomas R., Lancaster W.D., Gregoire L. Human papillomavirus type, proliferative activity, and p53: potential markers of aggressive papillomatosis. Arch. Pathol. Lab. Med. 2000, 124:721-724.
86. Moore C.E., Wiatrak B.J., McClatchey K.D., Koopmann C.F., Thomas G.R., Bradford C.R., Carey T.E. High-risk human papillomavirus types and squamous cell carcinoma in patients with respiratory papillomas. Otolaryngol. Head Neck Surg. 1999, 120:698-705.
87. Miller C.S., Johnstone B.M. Human papillomavirus as a risk factor for oral squamous cell carcinoma: a meta-analysis, 1982-1997. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2001, 91:622-635.
88. Uobe K., Masuno K., Fang Y.R., Li L.J., Wen Y.M., Ueda Y., Tanaka A. Detection of HPV in Japanese and Chinese oral carcinomas by in situ PCR. Oral Oncol. 2001, 37:146-152.
89. C.K. Stephen JK, Shah V, Havard S, Kapke A, Lu M, Benninger MS, Worsham MJ, DNA hypermethylation markers of poor outcome in laryngeal cancer. Clin. Epigenetics 1 (2010).
90. Danahey D.G., Tobin E.J., Schuller D.E., Bier-Laning C.M., Weghorst C.M., Lang J.C. P16 mutation frequency and clinical correlation in head and neck cancer. Acta Otolaryngol. 1999, 119:285-288.
91. Lydiatt W.M., Davidson B.J., Schantz S.P., Caruana S., Chaganti R.S. 9p21 deletion correlates with recurrence in head and neck cancer. Head Neck 1998, 20:113-118.
92. Shintani S., Nakahara Y., Mihara M., Ueyama Y., Matsumura T. Inactivation of the p14(ARF), p15(INK4B) and p16(INK4A) genes is a frequent event in human oral squamous cell carcinomas. Oral Oncol. 2001, 37:498-504.
93. Uesugi H., Uzawa K., Kawasaki K., Shimada K., Moriya T., Tada A., Shiiba M., Tanzawa H. Status of reduced expression and hypermethylation of the APC tumor suppressor gene in human oral squamous cell carcinoma. Int. J. Mol. Med. 2005, 15:597-602.
94. Wan H., Oridate N., Lotan D., Hong W.K., Lotan R. Overexpression of retinoic acid receptor beta in head and neck squamous cell carcinoma cells increases their sensitivity to retinoid-induced suppression of squamous differentiation by retinoids. Cancer Res. 1999, 59:3518-3526.
95. Youssef E.M., Lotan D., Issa J.P., Wakasa K., Fan Y.H., Mao L., Hassan K., Feng L., Lee J.J., Lippman S.M., Hong W.K., Lotan R. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin. Cancer Res. 2004, 10:1733-1742.
96. Toyota M., Sasaki Y., Satoh A., Ogi K., Kikuchi T., Suzuki H., Mita H., Tanaka N., Itoh F., Issa J.P., Jair K.W., Schuebel K.E., Imai K., Tokino T. Epigenetic inactivation of CHFR in human tumors. Proc. Natl. Acad. Sci. USA 2003, 100:7818-7823.